AnGes, Inc.
Stock Price Chart
2026/10/16 17:19 UpdatedPrice Trend
2026/10/16 17:19 UpdatedPrice & Trading Details
2026/10/16 17:19 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/10/01Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Intl Small Cap ETF
|
85.6K | +1.42% |
Financial Performance
2026/10/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥67M | ¥153M | ¥644M | ¥874M |
| Gross Profit | -¥27M | ¥19M | ¥248M | ¥320M |
| Operating Income | -¥16,317M | -¥11,968M | -¥9,109M | -¥5,145M |
| Pretax Income | -¥16,317M | -¥11,968M | -¥9,109M | -¥5,145M |
| Net Income | -¥14,715M | -¥7,438M | -¥28,129M | -¥5,123M |
| EPS | -¥94.29 | -¥39.29 | -¥119.53 | -¥14.44 |
| Operating Margin | -24,331.65% | -7,822.66% | -1,415.31% | -588.64% |
| Balance Sheet | ||||
| Total Assets | ¥38,821M | ¥28,893M | ¥4,669M | ¥5,406M |
| Total Equity | ¥30,425M | ¥26,103M | ¥2,157M | ¥3,076M |
| Total Liabilities | ¥8,395M | ¥2,789M | ¥2,512M | ¥2,330M |
| Cash | ¥11,035M | ¥4,160M | ¥1,708M | ¥1,882M |
| Interest-bearing Debt | ¥1,156M | ¥363M | ¥272M | ¥54M |
| Equity Ratio | 78.37% | 90.35% | 46.19% | 56.90% |
| D/E Ratio | 0.04 | 0.01 | 0.13 | 0.02 |
| Cash Flow | ||||
| Operating CF | -¥11,214M | -¥8,746M | -¥6,613M | -¥5,750M |
| Investing CF | -¥97M | -¥357M | -¥131M | ¥19M |
| Financing CF | ¥3,573M | ¥2,036M | ¥4,202M | ¥5,902M |
| Free CF | -¥11,234M | -¥8,835M | -¥6,690M | -¥5,765M |
| Efficiency | ||||
| ROE | -48.36% | -28.49% | -1,304.33% | -166.55% |
| ROA | -37.90% | -25.74% | -602.51% | -94.77% |
Latest IR Information
-
Announcement of Grant Award to Support Development of Subcutaneous Formulation of Co-developed Tie2 Receptor Agonist (AV-001)
Announced receipt of up to 280,347 Canadian dollars in funding and advisory services from NRC IRAP to support development of a subcutaneous formulation of co-developed AV-001. Introduction of subcutaneous administration is expected to expand dosing options and enable earlier intervention.
Read more -
Notice Regarding Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Clause
AnGes, Inc. announced the September exercise status for the 47th stock acquisition rights with an exercise price adjustment clause. For the subject month, the number of shares to be delivered was 6,361,700 shares; the number of exercised stock acquisition rights...
Read more -
Announcement of Completion of Subject Enrollment in the Early Phase 2 Clinical Trial of Co-developed Tie2 Receptor Agonist (AV-001)
Announced completion of subject enrollment for the co-developed product AV-001 in the early phase 2 clinical trial. Progresses to data analysis in a disease area granted FDA Fast Track designation; no direct impact on consolidated results for the fiscal year...
Read more -
Initiatives to Enhance Corporate Value through Business Partnership with Growth Partners
Through a business partnership with GP, accelerate overseas expansion and maximize the value of the drug discovery pipeline. In addition to capital provision, receive hands-on support including management support, business development, and DX promotion, and pursue strengthened domestic and international...
Read more -
Announcement on Completion of Acquisition and Cancellation of the 46th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Acquired and cancelled 837,171 units of the 46th stock acquisition rights. Total acquisition price: 27,626,643 yen. Remaining rights after cancellation: 0. Expected minimal impact on consolidated results for the fiscal year ending December 2026.
Read more
Latest News (5 items)
Company Information
About
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
